Skip to main content
Log in

Pain Biomarkers

  • Review Article
  • Part 2: Insights into the Future of Pain Management
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

The value of biomarkers in aiding early diagnosis of disease and predicting response to pharmacologic interventions is well known. The idea that biomarkers may also be used to identify and quantify pain has been investigated in preclinical and clinical studies. Findings from a preclinical study show that inflammatory pain and neuropathic pain have different biomarkers. Further investigations provided mixed results, on the one hand, cystatin C levels in cerebrospinal fluid appear to be a predictive marker for postherpetic neuralgia in patients with varicella-zoster virus, and a pain marker in women experiencing labour pain, but is not correlated with pain duration or intensity. Investigations into potential biomarkers for chest pain showed that cardiac markers used to aid in diagnosis and prognosis of cardiac disease correlate with tissue damage rather than with pain. Further studies are needed to gain insights into biomarkers for pain to enhance pain management practices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Biomarkers Definition Working Group-Bethesda Md. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95

    Article  Google Scholar 

  2. Kalso E. Biomarkers for pain [editorial]. Pain 2004; 107: 199–201

    Article  Google Scholar 

  3. Xiao Z, Prieto D, Conrads TP, et al. Proteomic patterns: their potential for disease diagnosis. Mol Cell End 2005; 230: 95–106

    Article  CAS  Google Scholar 

  4. Gineste C, Ho L, Pompl P, et al. High-throughput proteomics and protein biomarker discovery in an experimental model of inflammatory hyperalgesia: effects of nimesulide. Drugs 2003; 63: 23–9

    Article  CAS  Google Scholar 

  5. Cornefjord M, Nyberg F, Rosengren L, et al. Cerebrospinal fluid biomarkers in experimental spinal nerve root injury. Spine 2004; 29: 1862–8

    Article  Google Scholar 

  6. Empl M, Renaud S, Erne B, et al. TNFα expression in painful and nonpainful neuropathies. Neurology 2001; 56: 1371–7

    Article  CAS  Google Scholar 

  7. Sorkin LS, Xiao WH, Wagner R, et al. TNF-α induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 1997; 81: 255–62

    Article  CAS  Google Scholar 

  8. Uceyler N, Rogausch J, Toyka KV, et al. Differential expression of cytokines in painful and painless afferent neuropathies. Neurology 2007; 69: 42–9

    Article  CAS  Google Scholar 

  9. Raffaeli W, Samolsky BG, Landuzzi D, et al. Nociceptin levels in the CSF of chronic pain patients with or without intrathecal administration of morphine. J Pain Symptom Manage 2006; 32: 372–7

    Article  CAS  Google Scholar 

  10. Brisby H, Olmarker K, Rosengren L, et al. Markers of nerve injury in the CSF in patients with lumbar disc herniation and sciatica. Spine 1999; 24: 742–6

    Article  CAS  Google Scholar 

  11. Brisby H, Olmarker K, Larsson K, et al. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 2002; 11: 62–6

    Article  CAS  Google Scholar 

  12. Kuiper JI, Verbeek JH. Exploration of the use of biomarkers to monitor recovery after surgery for lumbar disc herniation: a prospective cohort study. J Spinal Disord 2002; 15: 398–403

    Article  Google Scholar 

  13. Zak-Prelich M, McKenzie RC, Sysa-Jedrzejowska A, et al. Local immune responses and systemic cytokine responses in zoster: relationship to the development of postherpetic neuralgia. Clin Exp Immunol, 2003; 131: 318–23

    Article  CAS  Google Scholar 

  14. Kotani N, Kudo R, Sakurai Y, et al. Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med 2004; 116: 318–24

    Article  CAS  Google Scholar 

  15. Mannes AJ, Martin BM, Yang HYT, et al. Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 2003; 102: 251–6

    Article  CAS  Google Scholar 

  16. Eisenach JC, Thomas JA, Rauck RL, et al. Cystatin C in cerebrospinal fluid is not a diagnostic test for pain in humans. Pain 2004; 107: 207–12

    Article  CAS  Google Scholar 

  17. Jaffe AS. Use of biomarkers in the emergency department and chest pain unit. Cardiol Clin 2005; 23: 453–65

    Article  Google Scholar 

  18. Januzzi JL, Martinez A. Cardiac biomarker testing for chest pain evaluation: where are we heading? Emerg Med Crit Care Rev 2006, 25–7

Download references

Acknowledgements

English language assistance for the preparation of this manuscript was provided by Stephanie Blick, Wolters Kluwer Health Medical Communications. This assistance was funded by Molteni Farmaceutici, Inc. The authors have no conflicts of interest, actual or potential, to report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Renato Vellucci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marchi, A., Vellucci, R., Mameli, S. et al. Pain Biomarkers. Clin. Drug Investig. 29 (Suppl 1), 41–46 (2009). https://doi.org/10.2165/0044011-200929001-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0044011-200929001-00006

Keywords

Navigation